



Source details

Journal of Comprehensive Pediatrics

Scopus coverage years: 2013, from 2015 to Present

Publisher: Brieflands

ISSN: 2251-8150 E-ISSN: 2251-8177

Subject area: Medicine: Pediatrics, Perinatology and Child Health

Source type: Journal

CiteScore 2021

0.8



SJR 2021

0.176



SNIP 2021

0.356



[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

Improved CiteScore methodology

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021

$$0.8 = \frac{129 \text{ Citations 2018 - 2021}}{153 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022

$$0.8 = \frac{118 \text{ Citations to date}}{146 \text{ Documents to date}}$$

Last updated on 05 April, 2023 • Updated monthly

CiteScore rank 2021

Category	Rank	Percentile
Medicine		
Pediatrics, Perinatology and Child Health	#202/298	32nd

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)



SJR

Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

[Home](#)[Journal Rankings](#)[Country Rankings](#)[Viz Tools](#)[Help](#)[About Us](#)

Journal of Comprehensive Pediatrics

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
<p>Iran</p> <p> Universities and research institutions in Iran</p> <p> Media Ranking in Iran</p>	<p>Medicine</p> <ul style="list-style-type: none"> Pediatrics, Perinatology and Child Health 	Brieflands	9
PUBLICATION TYPE	ISSN	COVERAGE	
Journals	22518177, 22518150	2013-2022	

SCOPE

Information not localized

Join the conversation about this journal

[Quartiles](#)

FIND SIMILAR JOURNALS ?

<p>1 Sri Lanka Journal of Child Health LKA</p> <p>58% similarity</p>	<p>2 Iranian Journal of Pediatrics IRN</p> <p>57% similarity</p>	<p>3 European Journal of Pediatrics DEU</p> <p>55% similarity</p>	<p>4 World Journ CHN</p> <p>5 s</p>
--	--	---	---

SJR

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022
Value	0.10	0.14	0.11	0.13	0.14	0.21	0.16	0.18	0.17

Total Documents

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021
Count	2	1	25	35	40	45	45	45	38

Total Cites **Self-Cites**

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total Cites	0	0	0	5	15	30	55	50	65
Self-Cites	0	0	0	0	0	1	10	5	5

Citations per document

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021
4 years	0.00	0.00	0.00	0.05	0.25	0.35	0.50	0.45	0.65
3 years	0.00	0.00	0.00	0.05	0.25	0.35	0.50	0.45	0.55
2 years	0.00	0.00	0.00	0.05	0.25	0.35	0.50	0.45	0.45

External Cites per Doc **Cites per Doc**

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021
External Cites per Doc	0.00	0.00	0.00	0.05	0.25	0.40	0.45	0.55	0.55
Cites per Doc	0.00	0.00	0.00	0.05	0.25	0.40	0.55	0.55	0.55

% International Collaboration

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021
Percentage	0	0	4	4	3	0	3	8	3

Citable documents **Non-citable documents**

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021
Citable Documents	0	0	10	30	60	85	105	115	125
Non-citable Documents	0	0	0	0	0	0	0	0	0


Cited documents **Uncited documents**

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021
Cited Documents	0	0	10	30	60	85	105	115	125
Uncited Documents	0	0	0	0	0	0	0	0	0

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç
```



Journal of Comprehensive Pediatrics


Q3 Pediatrics, Perinatology and Child Health
best quartile

SJR 2022
0.17

powered by scimagojr.com

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool.**



Metrics based on Scopus® data as of April 2023



Shivaprasad Kadole 2 years ago

Want to publish articles

← reply



Melanie Ortiz 2 years ago

SCImago Team

Dear Shivaprasad, thank you very much for your comment, we suggest you look for the author's instructions/submission guidelines in the journal's website. Best Regards,
SCImago Team

Leave a comment

Name

Email

(will not be published)

- **Published papers in this journal:** 2 out of 376 published article
- **Paid Salary:** Journal of Comprehensive Pediatrics
- Monetary or in kind compensation for self or household member from an organization that may in any way gain or lose financially or in any other way from the publication of papers in Brieflands:
 - **Reimbursement for attending a conference or symposium, Accommodation and travel or Fees for speaking:** No
 - **Fees for organizing education or funds for researches from Publisher:** No
 - **Stocks or shares in Publisher:** No
 - **Other competing interests related to the journal:** Not Declared

Editor in Chief

Mohammadreza Boloursaz

- *Professor, MD*
- **Affiliation:** Department of Pediatrics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#)
- **Published papers in this journal:** 13 out of 376 published article
- **Paid Salary:** Journal of Comprehensive Pediatrics
- Monetary or in kind compensation for self or household member from an organization that may in any way gain or lose financially or in any other way from the publication of papers in Brieflands:
 - **Reimbursement for attending a conference or symposium, Accommodation and travel or Fees for speaking:** No
 - **Fees for organizing education or funds for research from Publisher:** No
 - **Stocks or shares in Publisher:** No
 - **Other competing interests related to the journal:** Not Declared



Managing Editor

Parisa Bahmani



- *Ph.D*
- **Affiliation:** Tehran, Iran
- **Published papers in this journal:** 1 out of 376 published article

Associate Editors:



- MD
- Pediatricians, Tehran, Iran
- **Profiles:** [ResearchGate](#)



- MD
- Iran
- **Profiles:** [ResearchGate](#)

Farid Imanzadeh



- MD
- Shahid Beheshti university of medical sciences, Tehran, Iran
- **Profile:** [Scholar](#) | [ResearchGate](#)



Mohammadali Nilforooshan

- MD
- Iran

Gholamreza Khatami



- *Professor, MD*
- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)



Maryam Razzaghy- Azar

- MD
- Iran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Katayoun Khatami



- MD
- Shahid Beheshti University of Medical Sciences Tehran Iran
- **Profiles:** [ResearchGate](#)

Editorial Board:

Yahya Aghighi



- *Professor*
- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)



Alipasha Meysamie

- MD
- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#) | [ResearchGate](#)

Abdolvahab Alborzi



- *Professor*
- Shiraz University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#) | [ResearchGate](#)



Parisa Mohagheghi

- Iran university of medical sciences, Tehran, Iran
- **Profiles:** [Scholar](#)



- *Professor Emeritus*
- Rush University Medical Center, USA
- **Profiles:** [Scholar](#) | [ResearchGate](#)



- *MD*
- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Mahmoudreza Ashrafi



- *Professor*
- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#) | [ResearchGate](#)



Moinfar Mohammadreza

- USA



Hossein Fakhraei

- Iran



Abbas Momenzadeh

- Iran



Hossein Gharib

- USA



Guido Nikkhah

- University Medical Center Freiburg, Germany
- **Profiles:** [ResearchGate](#)



Nader Gordjani

- University of Wuerzburg, Germany
- **Profiles:** [ResearchGate](#)



Alireza Ranjbar

- Germany
- **Profiles:** [ResearchGate](#)



Enver Hasanoglu

- American Pediatric Society
- **Profiles:** [ResearchGate](#)



Nosratollah Razi

- Razi



Manouchehr Karjoo

- USA



Saeid Safari

- Iran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)



Hadi Samaei



Ali Kaviani

Iraj Sedighi



- Hamadan University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#)

Roya Kelishadi



- *Professor*
- Isfahan University of Medical Sciences, Isfahan, Iran
- **Profiles:** [Scholar](#) | [ResearchGate](#)

Abolghasem Sepehrnia



- St.Clemens Hospital Geldern, Germany
- **Profiles:** [ResearchGate](#)

Sibylle Koletzko



- University of Warmia and Mazury in Olsztyn, Poland
- **Profiles:** [ResearchGate](#)

Mohammadhossein Soltanzadeh



- Iran
- **Profiles:** [ResearchGate](#)

Berthold Koletzko



- *MD, Ph.D*
- Children's Hospital and Children clinic at the Dr. von Hauner Children's Hospital, Germany
- **Profiles:** [Scholar](#) | [ResearchGate](#)

Hania Szajewska



- Medical University of Warsaw, Poland
- **Profiles:** [Scholar](#) | [ResearchGate](#)

Fereidoon Zanganeh



- Usa

Aliakbar Velayati



- Shahid Beheshti University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Hossein Malekafzali



- *Ph.D*
- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Murat Yurdakok



- Hacettepe University, Ankara, Turkey
- **Profiles:** [ResearchGate](#)

Alireza Marandi



- Iran

Kaveh Abri Aghdam



- *Assistant Professor*
- Iran University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#)

Firooz Madadi



- Shahid Beheshti Medical University, Tehran, Iran

Samad EJ Golzari



- Tabriz University of Medical Sciences, Tabriz, Iran
- **Profiles:** [Scholar](#)

Mahmood Mohammadi



- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Reza Aminnejad



- Qom University of medical sciences, Qom, Iran
- **Profiles:** [Scholar](#)

Masoud Mohseni



- *Associate professor*
- Iran University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#)

Mohammadtaghi Arzanian



- Shahid Beheshti University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Saeed Mojtahedzadeh



- Shahid Beheshti University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Masoud Movahedi



- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Shahin Behjati



- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Samileh Noorbakhsh



- Iran
- **Profiles:** [Scholar](#)

Abdollah Karimi



- Shahid Beheshti University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#)

Hassan Otookesh



Mohammadreza Esmaeili



Ali Rabbani



- *Professor*
- Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#)

Javad Feiz



- Iran

Aliakbar Rahbarimanesh



- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Mohammad Ghofrani



- Iran

Asghar Ramyar



- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Mahmood Haghightat



- Shiraz University of medical Sciences, Shiraz, Iran
- **Profiles:** [Scholar](#)

Esmaeil Sadeghi



- Iran

Behrooz Jalili



- Iran

Sara Sanii



- *Assistant Professor*
- Shahid Beheshti University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#)

Parviz Tabatabaei



- University of Tehran, Tehran, Iran
- **Profiles:** [ResearchGate](#)

Hassan Soleimanpour



- Tabriz University of Medical Sciences, Tabriz, Iran
- **Profiles:** [Scholar](#)

Armen Kocharian



- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [ResaerchGate](#)

Methodology:



- *Associate Professor*
- Rajaie Cardiovascular Research Center, Iran University of Medical Sciences
- **Profiles:** [Scholar](#)

Mandi Zamani



- *MD*
- Tehran University of Medical Sciences, Tehran, Iran
- **Profiles:** [Scholar](#)

Language Editor:



Safnek Corporation

Tehran, Iran

How to contact Editorial Board?

To contact one of the above-mentioned boards or staff we kindly invite you to submit a ticket to the publisher with complete details. Our colleagues in the Support department will review your ticket and reply to you as soon as possible. Your tickets are more than welcomed via "Submit a Ticket" at: <https://brieflands.com/support>



Journal of Comprehensive Pediatrics

Pricing

[Home](#)

[Instructions](#)

About Journal

- [Publication Ethics And Publication Malpractice Statement](#)
- [Journal Metrics](#)
- [Contact Us](#)
- [Journal Information](#)
- [Boards And Committees](#)
- [Indexing And Listing Sources](#)
- [Open Peer Review \(OPR\)](#)

Articles

- [All Issues](#)
- [Current Issue](#)
- [In Press](#)
- [Accepted Manuscripts](#)



Submit a Ticket





Science, Technical, Medical Publisher


Since 2007

© Copyright 2023 Reserved by Brieflands.

Navigate to




 **Archive**
Vol. 14, Issue 2

 **9 Articles**
 May 2023



 **Research Article**

Effectiveness of Overshadowing by Flavored Candies in Management of Chemotherapy-Induced Nausea and Vomiting in Children with Leukemia: A Randomized Trial

 Ali Omidi , Manijeh Firoozi, Mehdi Khabazkhoob, Tido von Schoen-Angerer, Nasrin Mehrnoosh, Maryam Rassouli 



Final Published



 **Review Article**

Childhood Body Mass Index (BMI) and the Risk of Infection: A Narrative Review

 Houman Hashemian , Mohammad Ali Esfandiari , Setila Dalili 

Table 2. Total Score of Sleep Disorders Scale and It is Subscale in Children with Functional Constipation

Variable	Frequency	Mean ± SD
Total score	100	45.51 ± 6.79
Resistance to sleep	100	30.29 ± 3.99
Delayed sleeping	100	1.54 ± 0.34
Sleep duration	100	4.30 ± 0.30
Sleep anxiety	100	4.01 ± 0.35
Nocturnal awakenings	100	4.00 ± 0.00
Parasomnias	100	0.84 ± 0.29
Sleep apnea	100	3.27 ± 0.40
Daytime sleepiness	100	40.57 ± 4.39

Table 3. Compare Sleep Disorders Status in the Age and Sex Subgroups of Children with Functional Constipation


Variable	Sleep Disorders	
	Yes, Frequency (%)	No, %
Sex		
Female	29(24.0)	
Male	49(23.0)	
Age (yr)		
1-4	49(24.2)	
5-12	49(24.0)	

Research Article

The Prevalence of Sleep Disorders Among Children with Chronic Functional Constipation, a Study in Arak, Iran

Mahshid Maleki, Mojtaba Hashemi*, Maryam Zamanian, Mehran Shayganfard, Parsa Yousefichaijan

Final Published



Research Article

Medication Adherence in Children with Down Syndrome with Autoimmune Thyroid Disease During the COVID-19 Pandemic: Indonesian Study

Yuni Hisbiyah , Anang Endaryanto *, Bagus Setyoboedi , Wika Yuli Deakandi , Nur Rochmah , Muhammad Faizi

Final Published



If you have any questions [contact us](#)

Journal of Comprehensive Pediatrics

Pricing

[Home](#)

[Instructions](#)

About Journal

- [Publication Ethics And Publication Malpractice Statement](#)
- [Journal Metrics](#)
- [Contact Us](#)
- [Journal Information](#)
- [Boards And Committees](#)
- [Indexing And Listing Sources](#)
- [Open Peer Review \(OPR\)](#)

Articles

- [All Issues](#)
- [Current Issue](#)
- [In Press](#)
- [Accepted Manuscripts](#)



[Submit a Ticket](#)



Medication Adherence in Children with Down Syndrome with Autoimmune Thyroid Disease During the COVID-19 Pandemic: Indonesian Study

Yuni Hisbiyah ^{1,2}, Anang Endaryanto ^{1,2,*}, Bagus Setyoboedi ^{1,2}, Wika Yuli Deakandi ³, Nur Rochmah ² and Muhammad Faizi ²

¹Faculty of Medicine, University of Airlangga, Surabaya, East Java, Indonesia

²Department of Child Health, Faculty of Medicine, Dr. Soetomo General Hospital, University of Airlangga, Surabaya, East Java, Indonesia

³Faculty of Medicine, University of Islam Malang, Malang, East Java, Indonesia

*Corresponding author: Faculty of Medicine, University of Airlangga, Surabaya, East Java, Indonesia. Email: anang.endaryanto@fk.unair.ac.id

Received 2022 December 11; Revised 2023 February 15; Accepted 2023 February 22.

Abstract

Background: The coronavirus disease-19 (COVID-19) pandemic has significantly affected healthcare systems. Down syndrome (DS) is a chronic disease caused by trisomy of chromosome 21 which is associated with a variety of medical problems such as autoimmune thyroid disease (AITD) that necessitate comprehensive routine treatment. During the COVID-19 pandemic, there was an increasing unavailability, which became an impediment to chronic disease patients' drug consumption.

Objectives: The purpose of this study was to examine the barriers to medication adherence faced by DS patients during the COVID-19 pandemic.

Methods: An observational analytic study was conducted from January to July 2021 among parents of DS patients who registered in the pediatric endocrinology outpatient clinic of Dr. Soetomo General Hospital. Inclusion criteria include: The parents of DS with AITD patients aged 1-18 years who came to the pediatric endocrinology polyclinic, routinely took oral medication before March 2020, can fill out questionnaire forms independently, and signed the informed consent. Exclusion criteria were parents of DS patients who did not take regular medication, or started treatment after March 2020. Data were collected and analyzed using the Wilcoxon comparison test

Results: There are 31 DS patients responded and completed the questionnaires. Adherence to hospital visits in DS with AITD patients before and during the COVID-19 pandemic showed significant differences ($P=0.001$). The main barriers to follow-up visits during the pandemic were lockdown protocol which made travel difficult (28%). The compliance for taking medication was still high although 13 (41.9%) obtained the medicine without a prescription.

Conclusions: Changes in terms of medication adherence during the pandemic have highlighted the importance of improving DS patient's access to healthcare. Shifting medication counseling to the nearest primary health care provider with supervision from a tertiary referral specialist appears to be a reasonable and potentially cost-effective strategy in improving treatment adherence especially in a pandemic setting.

Keywords: Medication Adherence, Down Syndrome, Autoimmune thyroid disease, COVID-19, Lockdown, Chronic Disease Management

1. Background

The coronavirus disease-19 (COVID-19) pandemic has significantly affected various sectors, especially the healthcare systems in all over the world (1). Indonesia is the largest archipelago with the fourth largest population in the world. Despite its size and diversity, the country shares several features with other densely population such as India, Brazil and the United States which are known to have been severely impacted by the COVID-19 pandemic (1). In-

sufficient number of medical personnels, fragile medical supply chain, inadequate of health infrastructure to deal with increasing cases of COVID-19 were serious problems faced by health services in Indonesia. In addition, the optimal of patient referral system and the suboptimally limited capacity of the health care system to provide essential health services in prolonged emergency conditions has an impact on reducing the quality of services for non-COVID cases such as patients with chronic disease (2).

Down syndrome (DS) is a chronic disease known to be due to trisomy of chromosome 21 that is associated with risk for recurrent infections, autoimmune diseases, and inflammatory conditions (3), as a result of immune dysregulation (4). Chromosome 21 in DS patients saves many genes involved in immune response regulation, and its over-expression causes an overactive immune system due to chronic interferon hyperactivity even in the absence of infection (5). Severe COVID-19 can result in an uncontrollable immune response and multi-organ failure (6), making individuals with trisomy 21 at relatively high risk for more severe symptoms, increased hospitalization, and even death (4). In spite of the emergency risks faced by children with DS, they also have increased risk of developing thyroid disease, especially autoimmune thyroid disease (AITD) which has the most common manifestation as Hashimoto's thyroiditis/autoimmune hypothyroidism. Hypothyroidism is a treatable cause of mental retardation. There for, the lack of appropriate treatment deepens the children's retardation as well as affecting their growth process in this already impaired population (7). Adequate management of patients with thyroid diseases remains essential during the pandemic, but it could be compromised because of healthcare service restrictions (8).

Medication adherence is defined as the degree to which the person's behavior corresponds with the agreed recommendations from a health care provider. Rate of adherence is usually reported as the percentage of the prescribed doses of the medication actually taken by the patient over a specified period. Complexity of adherence is the result of an interplay of a range of factors including patient views and attributes, illness characteristics, social contexts, access and service issues. Barriers to the effective use of medicines specifically include poor provider-patient communication, inadequate knowledge about a drug and its use, not being convinced of the need for treatment, fear of adverse effects of the drug, long term drug regimens, complex regimens that require numerous medications with varying dosing schedules, cost and access barriers (9). During the COVID-19 pandemic, there were extraordinary changes that impacted the health care system, one of which was the lack of availability or accessibility of drugs, which disrupted medication adherence for many chronic diseases patients who require repeat visits, follow-up, examination, refilling of prescriptions and access to health facilities had difficulty visiting the hospital and obtaining medicines, which puts them at risk of exacerbating the course of their disease (10-12). Several studies conducted on various cases of chronic disease in several countries have shown different results of medication adherence during the COVID-19 pandemic. Study in Type 1 diabetes mellitus (T1DM) reported missed insulin dose and glu-

ucose monitoring not done routinely during lockdown (11), a meta-analysis study of epilepsy as other chronic disease reported inadequate adherence to anti-seizure medication during the COVID-19 pandemic in Italy and Saudi, while study in Turkey reported the COVID-19 pandemic made patients more motivated and informed about drug compliance (13).

The consequences of non-adherence are drug wastage, disease progression, reduced functional ability, lower quality of life, increased use of medical resources such as hospital visits and hospitalizations (9). Economic studies reveal that non-compliance with prescribed regimens can result in serious health consequences including the risk of hospitalization increasing more than two times compared to the general population, increased emergency department visits with severe complications which have an impact on higher health financing (14). To our knowledge, there has been no study that examined medication adherence in children with chronic disease in Indonesia during the COVID-19 pandemic as an archipelagic country with limited drug availability and travel barriers experienced by patients and their families.

2. Objectives

This study aims to evaluate medication adherence in Indonesian Down Syndrome children with AITD during the COVID-19 Pandemic and explore several causative factors.

3. Methods

3.1. Sample and Study Designs

An observational analytic study was conducted at tertiary referral teaching Dr. Soetomo Surabaya Hospital from January to July 2021. During that period, Indonesia currently undergoing the first wave of COVID-19. Local transportation and interdistrict/interstate communication are not allowed during the entire period. Consecutive sampling was performed from parents of DS with AITD patients enrolled in a pediatric endocrinology outpatient clinic. We contacted the telephone number recorded in the medical record and invited them to an online educational activity that contains about their illness and the importance of continuing treatment during the COVID-19 pandemic. Inclusion criteria were: (1) parents of DS patients who already diagnosed as AITD aged 1-18 years, (2) patients taking the oral medication for thyroid function (levothyroxine for patients with hypothyroidism and vitamin D for patients with euthyroidism) and regularly visit to our hospital before January 2020, (3) parents could fill out questionnaire

forms independently and signed informed consent for participants. The exclusion criteria included parents of DS patients who did not take medicine and those who received treatment after the pandemic was declared in Indonesia (March 2020). The sample size was calculated using the 'sample calculation formula' for an observational analytic study (15). This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethical committee of Dr Soetomo General Hospital, Surabaya Indonesia (Ref. No. 1960/KEKP/IV/2020).

3.2. Data Collection Tools

The data collection technique was carried out by filling out the on line questionnaires after education on line session. Informed consent was given before respondents answered the questionnaire. Respondents who did not fill out the questionnaire on that day were followed up regularly to fill out the questionnaire up to a maximum of 1 month after the online education session was held.

A self assessment questionnaire was administered consisting of (1) demographic and clinical data including patient age, gender, co-morbidity, regular treatment/daily doses, and duration of taking regular medication, parent's occupation, parent's educational background and salary per month, and distance traveled to the hospital which were extracted from the interview and medical record. (2) Questions regarding barriers to hospital visit and barriers to medication adherence during the pandemic were developed (Appendix 1 in Supplementary File). At our hospital, each patient will receive a statement regarding the next visit control schedule. According to the condition of the DS patient with AITD, the patient can be scheduled for routine control every 1 month or every 3 months. A patient is defined as compliant if he comes in the same month as scheduled. It is said to be disobedient if he comes in a different month. We define non-adherence if the patient misses a dose in ≥ 2 consecutive days or misses a dose in 1 day without adding an extra dose the next day (16).

Each question in the barrier of regular visit and medication adherence during pandemic was developed based on literature research. Unintentional non-adherence arises from capacity and resource constraints that prevent patients from implementing their decisions to follow treatment recommendations (eg problems accessing prescriptions, costs, competing demands) and sometimes involves individual constraints. While intentional non-adherence arises from beliefs, attitudes and expectations that affect the patient's motivation to start and stay with the treatment regimen (9, 17). Each question has been tested on 10 patients with other diagnoses in our clinic as a preliminary study and tested for validity and reliability.

3.3. Analysis of Data

Descriptive analysis was conducted to describe the demographic, clinical data and also detail the barriers to hospital visit and barriers to medication adherence during the pandemic. Statistical analysis using the Wilcoxon comparison test was performed to obtain the difference between adherence on regular visit and medication adherence before and during pandemic, with $P < 0.05$ considered as statistically significant. Statistical analysis was performed using Statistical Package for the Social Sciences version 17.0.

4. Results

Based on data recorded in medical records, we have a total of 42 DS patients with AITD in 2020. Unfortunately 3 patients died during the pandemic. Of the remaining 39 patients, there were 31 respondents (80%) who filled out the questionnaire completely. Table 1 describes the baseline characteristics of the sample. The mean duration of medication was 11.84 ± 17.69 months with the majority (51.8%) of patients taking 1 drug per day. The adherence to hospital visits was significantly higher before the COVID-19 pandemic compared with during the COVID-19 pandemic ($P = 0.001$), as seen in Table 2. There was no significant difference in the compliance for taking medication before and during the pandemic, but there were 18/31 (58.0%) patients who received non-prescription drugs from our clinic, the majority (41.9%) bought the drugs themselves. The most common hindrance faced by patients during the pandemic for a follow-up visit and taking medicine was the lockdown restrictions (28%) and medicine running out (50%), respectively.

5. Discussion

This study was conducted to identify the challenges of lockdown during COVID-19 and considering the importance of continuity of care in DS patients. The majority of patients in this study did not adhere to the medication control schedule and showed a significant difference in hospital visit compliance before and during the COVID-19 pandemic. This result is in line with other studies that showed the number of outpatient visits decreased during the COVID-19 pandemic (18, 19). Poor adherence is associated with increased emergency room visits, hospitalizations, and suboptimal clinical outcomes, leading to an increased burden on the health care system. During the pandemic, the decrease in routine visits is important factors that must be considered (20). We have data on 3 patients who died during the COVID-19 pandemic, which, although




Figure 1. Barrier to Hospital Visit Adherence during the COVID-19 Pandemic




Figure 2. Barrier to Take Medicine Regularly during the COVID-19 Pandemic

not shown to be directly associated with reduced adherence to treatment, is consistent with the results of other chronic disease studies showing increased morbidity and mortality of chronic disease patients over this period (11, 21).

In this study, the main reason for not visiting the hospital was the lockdown restrictions (28%), which led them

forgetting about the routine follow-up visit to the doctor. In addition, 15 (48.4%) patients in this study had to travel \geq 51 km for a hospital visit, thus making follow-up visits more difficult during lockdown restrictions. Many governments have had to make difficult decisions to protect their citizens in the face of the current pandemic, including lockdowns and restrictions on people's movements. Because of

Table 1. Demographic and Clinical Characteristics of the Study Participants

Parameters	No. (%) or Mean \pm SD (n = 31)
Age	40.97 \pm 32.64
Sex	
Male	18 (58.1)
Female	13 (41.9)
Mother's education	
Diploma/graduate	12 (38.7)
High school	17(54.8)
Middle school	1 (3.2)
Primary school middle school	1 (3.2)
Parent's income	
< 4,000,000 IDR	16 (51.6)
\geq 4,000,000 IDR	15 (48.4)
Distance traveled to the hospital, km	
< 51	16 (51.6)
\geq 51	15 (48.4)
Duration of oral medication, mo	11.84 \pm 17.69
The number of drugs that are routinely taken each day	
One drug	18 (58)
Two drugs	12 (38.8)
Three drugs or more	1 (3.2)
Congenital disease	
Yes	13 (41.9)
No	18 (58.1)
Thyroid dysfunction	
Yes	29 (93.5)
No	2 (6.5)
Thyroid autoimmune parameters, IU/mL	
Thyroid peroxidase antibody (TPO-Ab)	594.68 \pm 1565.074
Thyroglobulin antibody (Tg-Ab)	2036.93 \pm 2031.394

Abbreviation: IDR, Indonesian rupiahs.

the lockdown policy and the relocation of medical workers to the frontlines of the COVID-19 pandemic, 44% of patients with chronic conditions who require revisits, follow-ups, and medication refills may face difficulties due to limited access to health facilities and attending physicians. Furthermore, due to the increased risk of infection in hospitals, the majority of people avoid consulting their doctors (22, 23).

The second reason for the lack of adherence to visiting hospital is full-time employed parents (20%). Lock-

down protocol, which also makes schools and workplace closed, has forced many parents to do their work at home while also taking care of their children. This situation can be stressful for some of them and make them busier during this pandemic (24). Parents of children with special needs face additional challenges compared to other parents. They must look after their children, particularly the DS patients, whose behavior and emotions can be unpredictable. Taking care of their children, doing housework, and having to complete office work can be very demanding, thus making the parents busier and creating stressful situations. Mothers who have children with special needs are more likely to experience stress. When parents are busy, a lack of social awareness and support may cause the family to struggle to understand the children and, as a result, impede treatment planning (25).

Our study has also identified financial difficulties (12.50%) as a factor that can only worsen the patient's difficulty in visiting the hospital. Financial difficulties can prevent patients from receiving medicines, as up to 50% of respondents earned less than the minimum wage. Another study discovered that financial constraints have an impact on medication adherence and follow-up (26, 27). Most of the medical expenses for DS patients with AITD are covered by state insurance, but transportation costs have swelled due to the absence of public transport during the lockdown and the loss of livelihoods for some parents due to the pandemic are aggravating financial factors that make them not routinely take their children to visit the hospital.

In this study, non-adherence of hospital visit during pandemic was arises from capacity and resource constraints such as lock down, combined with individual constraints such as a full time employee and financial difficulty which is apart of un-intentional adherence (9). Recent studies indicate that unintentional nonadherence is significantly affected by beliefs about illness and medication or self-efficacy (28). There for, education about the disease and the importance of treatment is an important thing that must be done to increase adherence to hospital visits, in addition to bringing services closer to the patient's residence during the pandemic.

Our study found no difference between the compliance for taking medication before and during pandemic. This result in line with study in Turkey that reported during COVID-19 pandemic, patients more motivated and informed about drug compliance (13). The interesting thing is when this data is combined with how parents get routine medicines for their children, then there is approximately 41.9% of patients obtained their own medication during the pandemic. Self-medication (SM) as the selection and use of medicinal products by consumers to treat a self-recognized disease or the intermittent or continu-

Table 2. Participant's Response to the Questionnaire

Parameters	Respos to Questioner		P-Value
	Yes, (No. %)	No, (No. %)	
Adherence to hospital visit			0.001 ^a
Pre COVID-19	22 (70.97)	10 (32.26)	
During COVID-19	9 (29.03)	21 (67.74)	
Compliance for taking medication			0.544
Pre COVID-19	22 (71.0)	9 (29.0)	
During COVID-19	25 (80.6)	6 (19.4)	
How to get medicine during the COVID-19 pandemic			0.045 ^a
Buy them themselves	13 (41.9)	18 (58.1)	
Prescription from doctor in another hospital	5 (16.1)	26 (83.9)	
Prescription from doctor in dr Soetomo hospital	13 (41.9)	18 (58.1)	

^a Significance P-value < 0.05

ous use of drugs prescribed by a doctor for chronic or recurrent disease (29). The prevalence of SM is increasing sharply throughout the world, where the prevalence of self-medication in developing countries ranges from 12.7% to 95% (30). SM is one of the major contributors to making essential medicines accessible and affordable in developing countries. However, if not used as intended, it can lead to serious problems such as drug toxicity, drug interactions, drug dependence, microbial resistance and wasted medical resources.29 Unfortunately there has been a marked increase in self-medications without prescription during the pandemic (31).

Drugs running out during the onslaught of the COVID-19 pandemic has been determined as one of the main barriers in our study for patients to get regular therapy. The use of medicines prioritized for COVID-19 patients caused the supply of medicines for chronic diseases to dwindle; additionally, drug manufacturing companies were busy attempting to produce medicines and equipment aimed at dealing with COVID-19; moreover, the supply of imported medicines was also prioritized for COVID-19 patients, so essential medicines were not available or difficult to obtain for people with chronic diseases (23). The existence of travel restrictions that cause border closures, restrictions on trade between countries, and transportation problems have resulted in the disruption of national and international supply chain systems, including the supply of medicines (32). This data serves as a lesson for us that in the event of a pandemic, the availability of drugs for chronic cases cannot be secondary, because a break in the drug supply chain that causes patients to stop taking regular medication will become a big time bomb with an explosion of chronic cases that were neglected during the pan-

demic COVID-19.

The factors that contribute to poor medication adherence are numerous, not only those related to the health care system, but also those related to physicians (e.g., prescribing complex drug regimens, communication barriers, ineffective communication of information about side effects, and provision of care by multiple people), no less important are patient-related issues (e.g., suboptimal health literacy and lack of involvement in the treatment decision-making process) (33). Our study showed 42.9% of patients expressed ignorance about the importance of medication and 21.4% cited forgetting as a reason for not taking medication regularly. This data reflects the low knowledge of parents about their child's illness. In addition, only 38.7% of our respondents received education up to college. This is in accordance with other studies which show the higher the level of education, the better is the patient's knowledge about their medication (34).

The DS patients in this study had comorbidities, namely AITD, with the majority having thyroid dysfunction (93.5%). In addition, 41.9% of patients have congenital diseases that require strict medication adherence and continuous monitoring. As a result, the inability to do so will increase the risk of mortality and morbidity (35). The pandemic has exposed the fragility of the medical supply chain, the weakness of patient referral systems, and the health care system's limited capacity to deliver essential health services in protracted emergencies. Various strategies to overcome these mounting challenges must be developed to increase the capacity of health services. As an archipelagic country, Indonesia has major obstacles in accessing tertiary health services. By optimizing the role of general practitioners in public health centers spread

throughout Indonesia, cases that require tertiary services can be served through tiered referrals so that patients can be served and educated every month by general practitioners who have been supervised and will come to the tertiary hospital in 3 - 6 months to get subspecialty treatment. This system also needs to be considered to facilitate the provision of drugs and evaluation laboratory services needed in determining the next dose. Shifting medication counseling to the nearest primary health care provider with supervision from a tertiary referral specialist appears to be a reasonable and potentially cost-effective strategy in improving treatment adherence especially in a pandemic setting (36). This will provide an opportunity for patients and families to not self-administer their medication and they will benefit from different types of support by health-care professionals (37). Services for patients can also be brought closer through virtual visits (telemedicine). Although not applicable in all areas, this concept can be applied in urban areas in Indonesia with sufficient internet access and adequate transportation support for drugs and laboratory tests in these areas. The use of tele-health and digital health platforms has increased during the COVID-19 pandemic due to the implementation of physical distancing measures and restrictions. However, we must also be aware of the limitations faced by telemedicine services such as quality of care in terms of patient involvement, empathy, and emotional and human considerations, as well as concerns about practical safety and clinical, and security of medical data (38).

This study provides data on medication adherence during a pandemic and identifies various barriers experienced by patients. Existing data can be used as material for consideration in taking steps to improve the health system during the COVID-19 pandemic in Indonesia. Particular attention should be paid to the importance of storing chronic patient information within the health system, and the importance of tracking disease complications during the COVID-19 pandemic. In addition, training on the health care is important for preparing for a crisis situation like a war or invasion. The limitations of this study were limited number of samples due to very specific cases, and a single-centered study. Conducting a multi-center study to collect more data in another center in Indonesia during the COVID-19 pandemic will be beneficial.

5.1. Conclusions

The COVID-19 pandemic has crippled healthcare services around the world. There was a change in hospital visit and medication adherence during the COVID-19 pandemic, as has been determined in this study. Lockdown regulations and travel restrictions causing limiting medicine availability and raising the risk of morbidity and mortality

among children with DS. During the COVID-19 pandemic, parents' efforts to improve medication adherence by purchasing medicine without a prescription highlighted the need to increase the accessibility of medical care for DS patients. The health service approach strategy through a tiered referral system and telemedicine needs to be implemented carefully by considering all available resources in all regions in Indonesia which have different characteristics. Furthermore, training in health care is important in preparation for an emergency condition such as war or invasion, an emergency condition that might be experienced by the health system in Indonesia apart from the COVID-19 pandemic.

Supplementary Material

Supplementary material(s) is available [here](#) [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Acknowledgments

The authors would like to thank the patients, parents, and pediatric endocrine teams for their time and cooperation, which allowed us to finish this study.

Footnotes

Authors' Contribution: Conception or design: Yuni Hisbiyah, Nur Rochmah; Acquisition, analysis, or interpretation of data: Bagus Setyoboedi, wika yuli deakandi; Drafting the work or revising: Anang Endaryanto; Final approval of the manuscript: Bagus Setyoboedi, Muhammad Faizi.

Conflict of Interests: Funding or research support: None; Employment: None; Personal financial interests: None; Stocks or shares in companies: None; Consultation fees: None; Patents: None; Personal or professional relations with organizations and individuals (parents and children, wife and husband, family relationships, etc.): None; Unpaid membership in a government or non-governmental organization: None; Are you one of the editorial board members or a reviewer of this journal? No.

Data Reproducibility: The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available due to privacy.

Ethical Approval: This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethical committee of Dr Soetomo General Hospital, Surabaya Indonesia (Ref. No. 1960/KEKP/IV/2020).

Funding/Support: This research did not receive specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Informed Consent: Informed consent was given before respondents answered the questionnaire.

References

- Pepinski T. COVID-19 and Democracy in Indonesia: Short-Term Stability and Long-Term Threats. *Think Global Health*. 2021;**19**.
- Mahendradhata Y, Andayani N, Hasri ET, Arifi MD, Siahaan RGM, Solikha DA, et al. The Capacity of the Indonesian Healthcare System to Respond to COVID-19. *Front Public Health*. 2021;**9**:649819. [PubMed ID: 34307272]. [PubMed Central ID: PMC8292619]. <https://doi.org/10.3389/fpubh.2021.649819>.
- Pierce MJ, LaFranchi SH, Pinter JD. Characterization of Thyroid Abnormalities in a Large Cohort of Children with Down Syndrome. *Horm Res Paediatr*. 2017;**87**(3):170–8. [PubMed ID: 28259872]. [PubMed Central ID: PMC5483988]. <https://doi.org/10.1159/000457952>.
- Espinosa JM. Down Syndrome and COVID-19: A Perfect Storm? *Cell Rep Med*. 2020;**1**(2):100019. [PubMed ID: 32501455]. [PubMed Central ID: PMC7252041]. <https://doi.org/10.1016/j.xcrm.2020.100019>.
- Araya P, Waugh KA, Sullivan KD, Nunez NG, Roselli E, Smith KP, et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. *Proc Natl Acad Sci U S A*. 2019;**116**(48):24231–41. [PubMed ID: 31699819]. [PubMed Central ID: PMC6883781]. <https://doi.org/10.1073/pnas.1908129116>.
- Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. 2020;**45**(5):846–8. [PubMed ID: 32125452]. [PubMed Central ID: PMC7080116]. <https://doi.org/10.1007/s00134-020-05991-x>.
- Barg E, Chaćka D, Komar A. Endocrinological disorders associated with Down's syndrome. *Pediatr Pol*. 2006;**81**:844–9.
- Lisco G, De Tullio A, Jirillo E, Giagulli VA, De Pergola G, Guastamacchia E, et al. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. *J Endocrinol Invest*. 2021;**44**(9):1801–14. [PubMed ID: 33765288]. [PubMed Central ID: PMC7992516]. <https://doi.org/10.1007/s40618-021-01554-z>.
- Jimmy B, Jose J. Patient medication adherence: measures in daily practice. *Oman Med J*. 2011;**26**(3):155–9. [PubMed ID: 22043406]. [PubMed Central ID: PMC3191684]. <https://doi.org/10.5001/omj.2011.38>.
- Palmer K, Monaco A, Kivipelto M, Onder G, Maggi S, Michel JP, et al. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing. *Aging Clin Exp Res*. 2020;**32**(7):1189–94. [PubMed ID: 32458356]. [PubMed Central ID: PMC7248450]. <https://doi.org/10.1007/s40520-020-01601-4>.
- Verma A, Rajput R, Verma S, Balania VKB, Jangra B. Impact of lockdown in COVID 19 on glycemic control in patients with type 1 Diabetes Mellitus. *Diabetes Metab Syndr*. 2020;**14**(5):1213–6. [PubMed ID: 32679527]. [PubMed Central ID: PMC7357511]. <https://doi.org/10.1016/j.dsx.2020.07.016>.
- Emmanuel Awucha N, Chinelo Janefrances O, Chima Meshach A, Chiamaka Henrietta J, Ibilolia Daniel A, Esther Chidiebere N. Impact of the COVID-19 Pandemic on Consumers' Access to Essential Medicines in Nigeria. *Am J Trop Med Hyg*. 2020;**103**(4):1630–4. [PubMed ID: 32815509]. [PubMed Central ID: PMC7543821]. <https://doi.org/10.4269/ajtmh.20-0838>.
- Menon S, Sander JW. Effects of the COVID-19 pandemic on medication adherence: In the case of antiseizure medications, A scoping review. *Seizure*. 2021;**93**:81–7. [PubMed ID: 34717290]. [PubMed Central ID: PMC8526436]. <https://doi.org/10.1016/j.seizure.2021.10.009>.
- PharmacoEconomics & Outcomes News. Poor medication adherence increases healthcare costs. *Pharm Econ Outcomes News*. 2013;**480**(1):5. <https://doi.org/10.2165/00151234-200504800-00010>.
- Dahlan MS. [Statistics for medicine and health]. Penerbit Salemba; 2011. Indonesian.
- Kaufman AS, Morrison A. Patterns of non-adherence to oral antiretroviral medication: frequencies of consecutively missed doses. *Patient Prefer Adherence*. 2019;**13**:389–94. [PubMed ID: 30880923]. [PubMed Central ID: PMC6417850]. <https://doi.org/10.2147/PPA.S192153>.
- Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. *Am J Manag Care*. 2009;**15**(1):59–66. [PubMed ID: 19146365]. [PubMed Central ID: PMC2728593].
- Wakabayashi T, Sasaoka Y, Sakai Y, Hinotsu S, Kawasaki Y. Decrease in unscheduled pediatric outpatient visits due to SARS-CoV-2. *Pediatr Int*. 2022;**64**(1). e14748. [PubMed ID: 34724595]. [PubMed Central ID: PMC8662230]. <https://doi.org/10.1111/ped.14748>.
- Subathra GN, Rajendrababu SR, Senthilkumar VA, Mani I, Udayakumar B. Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India. *Indian J Ophthalmol*. 2021;**69**(5):1264–70. [PubMed ID: 33913874]. [PubMed Central ID: PMC8186660]. https://doi.org/10.4103/ijoo.IJO_164_21.
- Chudasama YV, Gillies CL, Zaccardi F, Coles B, Davies MJ, Seidu S, et al. Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. *Diabetes Metab Syndr*. 2020;**14**(5):965–7. [PubMed ID: 32604016]. [PubMed Central ID: PMC7308780]. <https://doi.org/10.1016/j.dsx.2020.06.042>.
- Alkhotani A, Siddiqui MI, Almutashri F, Baothman R. The effect of COVID-19 pandemic on seizure control and self-reported stress on patient with epilepsy. *Epilepsy Behav*. 2020;**112**:107323. [PubMed ID: 32712565]. [PubMed Central ID: PMC7359799]. <https://doi.org/10.1016/j.yebeh.2020.107323>.
- Nshimiyiro A, Barnhart DA, Cubaka VK, Dusengimana JMV, Dusabeyezu S, Ndagijimana D, et al. Barriers and coping mechanisms to accessing healthcare during the COVID-19 lockdown: a cross-sectional survey among patients with chronic diseases in rural Rwanda. *BMC Public Health*. 2021;**21**(1):704. [PubMed ID: 33838676]. [PubMed Central ID: PMC8035601]. <https://doi.org/10.1186/s12889-021-10783-z>.
- Kretchy IA, Asiedu-Danso M, Kretchy JP. Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries. *Res Social Adm Pharm*. 2021;**17**(1):2023–6. [PubMed ID: 32307319]. [PubMed Central ID: PMC7158799]. <https://doi.org/10.1016/j.sapharm.2020.04.007>.
- Spinelli M, Lionetti F, Pastore M, Fasolo M. Parents' Stress and Children's Psychological Problems in Families Facing the COVID-19 Outbreak in Italy. *Front Psychol*. 2020;**11**:1713. [PubMed ID: 32719646]. [PubMed Central ID: PMC7350926]. <https://doi.org/10.3389/fpsyg.2020.01713>.
- Alhuzimi T. Stress and emotional wellbeing of parents due to change in routine for children with Autism Spectrum Disorder (ASD) at home during COVID-19 pandemic in Saudi Arabia. *Res Dev Disabil*. 2021;**108**:103822. [PubMed ID: 33271447]. <https://doi.org/10.1016/j.ridd.2020.103822>.
- Lee BW, Sathyan P, John RK, Singh K, Robin AL. Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India. *Arch Ophthalmol*. 2008;**126**(10):1448–54. [PubMed ID: 18852425]. <https://doi.org/10.1001/archophth.126.10.1448>.
- Sleath BL, Krishnadass R, Cho M, Robin AL, Mehta R, Covert D, et al. Patient-reported barriers to glaucoma medication access, use, and adherence in southern India. *Indian J Ophthalmol*. 2009;**57**(1):63–8. [PubMed ID: 19075417]. [PubMed Central ID: PMC2661507]. <https://doi.org/10.4103/0301-4738.44495>.

28. Bae SG, Kam S, Park KS, Kim KY, Hong NS, Kim KS, et al. Factors related to intentional and unintentional medication nonadherence in elderly patients with hypertension in rural community. *Patient Prefer Adherence*. 2016;**10**:1979–89. [PubMed ID: 27729776]. [PubMed Central ID: PMC5047725]. <https://doi.org/10.2147/PPA.S114529>.
29. Shafie M, Eyasu M, Muzeyin K, Worku Y, Martin-Aragon S. Prevalence and determinants of self-medication practice among selected households in Addis Ababa community. *PLoS One*. 2018;**13**(3). e0194122. [PubMed ID: 29579074]. [PubMed Central ID: PMC5868796]. <https://doi.org/10.1371/journal.pone.0194122>.
30. Wijesinghe PR, Jayakody RL, de AR. Prevalence and predictors of self-medication in a selected urban and rural district of Sri Lanka. *WHO South East Asia J Public Health*. 2012;**1**(1):28–41. [PubMed ID: 28612776]. <https://doi.org/10.4103/2224-3151.206911>.
31. Dutta S, Kaur RJ, Bhardwaj P, Ambwani S, Godman B, Jha PA, et al. Demand of COVID-19 medicines without prescription among community pharmacies in Jodhpur, India: Findings and implications. *J Family Med Prim Care*. 2022;**11**(2):503–11. [PubMed ID: 35360769]. [PubMed Central ID: PMC8963618]. https://doi.org/10.4103/jfmpc.jfmpc_1250_21.
32. *Measles Cases and Outbreaks*. Centers for Disease Control and Prevention; 2021. Available from: <https://www.cdc.gov/measles/cases-outbreaks.html>.
33. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc*. 2011;**86**(4):304–14. [PubMed ID: 21389250]. [PubMed Central ID: PMC3068890]. <https://doi.org/10.4065/mcp.2010.0575>.
34. Alkatheri AM, Albekairy AM. Does the patients' educational level and previous counseling affect their medication knowledge? *Ann Thorac Med*. 2013;**8**(2):105–8. [PubMed ID: 23741273]. [PubMed Central ID: PMC3667438]. <https://doi.org/10.4103/1817-1737.109823>.
35. Pal R, Bhadada SK. Managing common endocrine disorders amid COVID-19 pandemic. *Diabetes Metab Syndr*. 2020;**14**(5):767–71. [PubMed ID: 32521463]. [PubMed Central ID: PMC7271862]. <https://doi.org/10.1016/j.dsx.2020.05.050>.
36. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keenanasseril A, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2014;**2014**(11). CD000011. [PubMed ID: 25412402]. [PubMed Central ID: PMC7263418]. <https://doi.org/10.1002/14651858.CD000011.pub4>.
37. Kvarnstrom K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence: a qualitative study with general practitioners. *BMJ Open*. 2018;**8**(1). e015332. [PubMed ID: 29362241]. [PubMed Central ID: PMC5786122]. <https://doi.org/10.1136/bmjopen-2016-015332>.
38. Bouabida K, Lebouche B, Pomey MP. Telehealth and COVID-19 Pandemic: An Overview of the Telehealth Use, Advantages, Challenges, and Opportunities during COVID-19 Pandemic. *Healthcare (Basel)*. 2022;**10**(11). [PubMed ID: 36421617]. [PubMed Central ID: PMC9690761]. <https://doi.org/10.3390/healthcare10112293>.